Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
The formulation is backed by over 80 clinical trials and 200 scientific publications
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The move is expected to be crucial during health crises
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion
Subscribe To Our Newsletter & Stay Updated